bluuebunny/crossref_metadata_2025_split huggingface dataset:
Trajectories of depressive symptoms and risk of cardiovascular disease, cancer and mortality: a prospective cohort study
Authors: Min Jiahao , Cao Zhi , Chen Han , Wang Xiaohe , Xu Chenjie 
Published: May 2024

BackgroundDepressive symptoms are established risk factors for various health outcomes. However, previous studies assessed depressive symptoms at a single time point, neglecting individual variations over time.AimsTo identify depressive symptoms trajectories through repeated measures and examine their associations with cardiovascular disease (CVD), cancer and mortality.MethodsThis study included 20 634 UK Biobank participants free of CVD and cancer at baseline with two or more assessments of depressive symptoms during 2006–2016. Group-based trajectory modelling identified depressive symptoms trajectories. Incident CVD, cancer and mortality were followed up until 2021 through linked registries.ResultsSix depressive symptoms trajectories were identified: no symptoms (n=6407), mild-stable (n=11 539), moderate-stable (n=2183), severe-decreasing (n=206), moderate-increasing (n=177) and severe-stable (n=122). During a median follow-up of 5.5 years, 1471 CVD cases, 1275 cancer cases and 503 deaths were documented. Compared with the no symptoms trajectory, the mild-stable, moderate-stable and severe-stable trajectories exhibited higher CVD risk, with hazard ratios (HRs) (95% CIs) of 1.19 (1.06 to 1.34), 1.32 (1.08 to 1.34) and 2.99 (1.85 to 4.84), respectively. Moderate-increasing and severe-stable trajectories were associated with higher mortality risks, with HRs (95% CIs) of 2.27 (1.04 to 4.93) and 3.26 (1.55 to 6.88), respectively. However, the severe-decreasing trajectory was not associated with higher risks of adverse outcomes. We did not find significant associations between any trajectory and cancer.ConclusionsTrajectories related to stable and increasing depressive symptoms, but not the trajectory associated with severe depressive symptoms at the initial assessment but decreasing at the follow-up, were associated with higher risks of CVD and mortality. Alleviating severe depressive symptoms at the initial onset may mitigate CVD and mortality risks.
Contour Neurovascular System for endovascular embolization of cerebral aneurysms: a multicenter cohort study of 10 European neurovascular centers
Authors: Griessenauer Christoph J , Ghozy Sherief , Biondi Alessandra , Hecker Constantin , Wodarg Fritz , Liebig Thomas , Patankar Tufail , Lamin Saleh , Martínez-Galdámez Mario , Cognard Christophe , Fiehler Jens , Dorn Franziska , Dmytriw Adam A , Killer-Oberpfalzer Monika 
Published: May 2024

BackgroundIntrasaccular devices have become increasingly popular in the treatment of cerebral aneurysms, particularly at the bifurcation. Here we evaluate the Contour Neurovascular System, an intrasaccular device for the endovascular treatment of cerebral aneurysms, in a multicenter cohort study, the largest to the best of our knowledge.MethodsConsecutive patients with intracranial aneurysms treated with the Contour Neurovascular System between February 2017 and October 2022 at 10 European neurovascular centers were prospectively collected and retrospectively reviewed. Patient and aneurysm characteristics, procedural details, and angiographic and clinical outcomes were evaluated.ResultsDuring the study period, 279 aneurysms (median age of patients 60 years, IQR 52–68) were treated with Contour. In 83.2% of patients the device was placed electively, whereas the remaining patients were treated in the setting of acute subarachnoid hemorrhage. The most common locations were the middle cerebral artery (26.5%) followed by the anterior communicating region (26.2%). Median aneurysm dome and neck size were 5.2 mm (IQR 4.2–7) and 3.9 mm (IQR 3–5). Contour size 7 (39%) and 9 (25%) were most used. Thromboembolic and hemorrhagic complications occurred in 6.8% and 0.4% of aneurysms, respectively. Raymond-Roy 1 and 2 occlusions at last follow-up were achieved in 63.2% and 28.3%, respectively, resulting in adequate occlusion of 91.5% of aneurysms.ConclusionThis is the largest multicenter study reporting the outcome on the Contour Neurovascular System. At 1 year, the self-evaluated data on safety and efficacy are comparable to data of existing intrasaccular devices. Contour is a promising technology in the treatment of cerebral aneurysms.
The pEGASUS-HPC stent system for intracranial arterial stenosis: a single-center case series
Authors: Pielenz Daniel , Klisch Joachim , Fiorella David , Gawlitza Matthias , Steinbrecher Andreas , Leinisch Elke , Lobsien Elmar , Hoffmann Karl-Titus , Lobsien Donald 
Published: May 2024

BackgroundIntracranial arterial stenting is a technique for the treatment of symptomatic stenosis. In this single-center retrospective case series we evaluated a novel low profile laser-cut stent with an antithrombogenic hydrophilic polymer coating (pEGASUS-HPC, Phenox GmbH, Bochum, Germany) for the treatment of intracranial stenosis in the setting of acute ischemic stroke and elective cases.MethodsAll patients treated with pEGASUS-HPC for one or more intracranial arterial stenoses at our institution were retrospectively included. Clinical, imaging and procedural parameters as well as clinical and imaging follow-up data were collected.ResultsWe performed 43 interventions in 41 patients with 42 stenoses in our neurovascular center between August 2021 and February 2024. Twenty-one patients (51.2%) were female and the mean±SD age was 71±10.8 years. Thirty-seven (86.1%) procedures were performed in the setting of endovascular acute ischemic stroke treatment. Technical or procedural complications occurred in seven patients (16.3%), six in the thrombectomy group and one in the elective group. One stent-related hemorrhagic complication (subarachnoid hemorrhage) occurred in emergency cases and symptomatic intracerebral hemorrhage occurred in one patient treated in an elective setting. Overall stenosis reduction following pEGASUS-HPC stent implantation was 53.0±18.0%. On follow-up imaging, which was available for 16 patients (37.2%) after an average of 32±58.6 days, 62.5% of the stents were patent.ConclusionOur single-center case series demonstrates the feasibility of using the pEGASUS-HPC stent system, especially in emergency situations when thrombectomy fails.
Fat intravasation, fat emboli and fat embolism syndrome in adult major trauma patients with intraosseous catheters: a systematic review
Authors: Ellington Matt , Hibberd O , Aylwin C 
Published: May 2024

IntroductionIntraosseous (IO) administration of medication, fluids and blood products is accepted practice for critically injured patients in whom intravenous access is not immediately available. However, there are concerns that high intramedullary pressures resulting from IO infusion may cause bone marrow intravasation and subsequent fat embolisation. The aim of this systematic review is to synthesise the existing evidence describing fat intravasation, fat embolism and fat embolism syndrome (FES) following IO infusion.MethodsA systematic search of CINAHL, MEDLINE and Embase was undertaken using the search terms “intraosseous”, “fat embolism”, “fat intravasation” and “fat embolism syndrome”. Two authors independently screened abstracts and full texts, against eligibility criteria and assessed risk of bias. A grey literature search (including references) was undertaken. Inclusion criteria were: all human and animal studies reporting novel data on IO-associated fat emboli. This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis.Results22 papers were identified from the search, with a further 5 found from reference lists. N=7 full papers met inclusion criteria. These papers were all translational animal studies. The overall risk of bias was high. Studies demonstrated that fat intravasation and fat embolisation are near universal after IO infusion, but of uncertain clinical significance. The initial IO flush appears to cause the highest intramedullary pressure and highest chance of fat intravasation and embolisation. No conclusions could be drawn on FES.ConclusionsIO catheters remain a useful intervention in the armamentarium of trauma clinicians. Although their use is widely accepted, there is a paucity of evidence investigating fat embolisation in IO infusions. Despite this, pulmonary fat emboli after IO infusion are very common. The existing data are of low quality with a high risk of bias. More research is needed to address this important subject.PROSPERO registration numberCRD42023399333.
Soil surface greenhouse gas emissions and hydro-physical properties as impacted by prairie cordgrass intercropped with kura clover
Authors: Varikuti Vaishnavi , Chakraborty Poulamee , Xu Suite , Mahal Navreet K. , Kumar Sandeep 
Published: May 2024

Prairie cordgrass (PCG) is a perennial crop which has the potential for biofuel production under marginal lands. The intercropping of a perennial legume, kura clover (KC) with PCG can reduce the use of chemical fertilizer while maintaining the soil hydro-physical conditions. The objective of this study was to compare the soil hydro-physical properties and greenhouse gas (GHG) fluxes under PCG intercropped with KC (PCG–KC), and PCG fertilized with graded levels of N (0, 75, 150, and 225 N kg ha−1). During the summer of 2021, soil samples (0–10 cm) were collected. Additionally, gas samples were collected weekly from April through September of the same year. Soil water retention, saturated hydraulic conductivity ( Ksat), thermal conductivity (λ), soil organic carbon (SOC), and total N (TN) concentrations were measured. Soil pore characteristics were measured using X-ray computed tomography. The PCG–KC had 1.42 g kg−1 TN and 24 g kg−1 SOC at 0–10 cm, non-significant to PCG-75, 150, and 225 N. Nonetheless, TN significantly increased in both PCG–KC and other fertilized treatments compared to the control. Intercropping boosted macroporosity (0.024 cm3 cm−3), Ksat (+50%), and lowered λ (−1%), compared to the N fertilized treatments. Soil cumulative CO2 under PCG–KC (1012.67 kg C ha−1) was similar to PCG-75, 150 N, but lower than PCG-225 N (1418.66 kg C ha−1). Overall, this study showed that PCG–KC can be a sustainable option over the use of N fertilizers since they had similar levels of hydro-physical characteristics and had a comparable ability to mitigate GHG emissions.
First-mover advantage in music
Authors: Sobchuk Oleg , Youngblood Mason , Morin Olivier 
Published: May 2024

AbstractWhy do some songs and musicians become successful while others do not? We show that one of the reasons may be the “first-mover advantage”: artists that stand at the foundation of new music genres tend to be more successful than those who join these genres later on. To test this hypothesis, we have analyzed a massive dataset of over 920,000 songs, including 110 music genres: 10 chosen intentionally and preregistered, and 100 chosen randomly. For this, we collected the data from two music services: Spotify, which provides detailed information about songs’ success (the precise number of times each song was listened to), and Every Noise at Once, which provides detailed genre tags for musicians. 91 genres, out of 110, show the first-mover advantage—clearly suggesting that it is an important mechanism in music success and evolution.
Abstract B010: Tumor B8T expression stratifies overall survival in high risk muscle invasive urothelial carcinoma
Authors: Elias Roy , Aragaki Adam K. , Hoffman-Censits Jean H. , Hahn Noah M. , McConkey David J. , Johnson Burles A. 
Published: May 2024

Abstract
Background and Objective: Determining novel biomarkers to identify patients that benefit and do not benefit from immune checkpoint inhibitor (ICI) therapy is critical to avoid overtreatment. Circulating tumor DNA (ctDNA) has emerged as a biomarker that associates with overall survival (OS) benefit to ICI in patients with muscle invasive urothelial carcinoma (MIUC). However, few studies have examined whether existing immune based biomarkers stratify OS within the high risk, ctDNA(+) population. Methods: To address this, we interrogated ctDNA and RNA sequencing data from the IMvigor010 dataset of patients with high risk MIUC after cystectomy who were randomized to adjuvant atezolizumab versus observation. We correlated OS with ctDNA positivity and expression of a B cell and CD8 T cell gene signature (B8T). Key Findings: In patients who were ctDNA(+), high tumor expression of a B cell gene signature (BCGS) associated with significantly higher OS when compared with patients with low tumor BCGS, regardless of whether patients were treated with atezolizumab. In ctDNA(+) patients with high tumor expression of both BCGS and CD8 T cell gene signature (CD8TGS), e.g. B8T high/high, atezolizumab did not associate with OS benefit. Conversely, in patients with B8T high/low tumors, receipt of adjuvant atezolizumab associated with significantly increased OS (p &lt; 0.001), and this benefit remained significant in multivariable analyses (p = 0.047). Notably, benefit with atezolizumab occurred in patients with B8T high/low tumors who were either ctDNA(+) (p = 0.057) or ctDNA(-) (p = 0.034). Conclusions and Clinical Implications: While tumor B8T high/high expression is a prognostic biomarker for OS in ctDNA(+) patients with high risk MIUC, these results suggest B8T high/low is a predictive biomarker for benefit from ICI. Moreover, in a small subset of patients who are ctDNA(-), tumor B8T high/low associates with benefit to ICI. This supports the utility of the B8T biomarker as a prognostic identifier in high risk MIUC, its ability to identify patients who will benefit from ICI regardless of ctDNA status, and for the first time ascertains a potential cohort of patients who are ctDNA(-) yet benefit from ICI.
Citation Format: Roy Elias, Adam K. Aragaki, Jean H. Hoffman-Censits, Noah M. Hahn, David J. McConkey, Burles A. Johnson III. Tumor B8T expression stratifies overall survival in high risk muscle invasive urothelial carcinoma [abstract]. In: Proceedings of the AACR Special Conference on Bladder Cancer: Transforming the Field; 2024 May 17-20; Charlotte, NC. Philadelphia (PA): AACR; Clin Cancer Res 2024;30(10_Suppl):Abstract nr B010.
Abstract B024: Development of HM-001 as a therapeutic drug for non-muscle invasive bladder cancer
Authors: Mima Shinji , Sakaki Monta , Kiya Noriaki , Kawashima Atsunari , Nonomura Norio , Kakinuma Chihaya 
Published: May 2024

Abstract
HM-001 is a drug containing sodium chlorite as the active ingredient that is being developed as a drug for non-muscle invasive bladder cancer (NMIBC), and is currently undergoing physician-led clinical trials. It has been discovered that sodium chlorite generates radicals in an acidic environment, and phosphatidylserine on the surface of tumor cells acts as a Lewis acid to generate radicals. HM-001, like other anticancer drugs and BCG, is intended to be injected into the bladder, retained, and then excreted. GLP studies using the same administration method has been completed, and no toxic changes have been observed in human trial doses. The efficacy of HM-001 against NMIBC was evaluated using an orthotopic transplantation model of UM-UC-3, a bladder cancer cell line. In the model, cells were transplanted into the bladder of SCID mouse after epithelial removal with trypsin, 600, 800, 1,600, and 3,200 ppm of HM-001 were administered once a week, and the weight of the excised bladder was calculated. After 4 weeks, the tumor weight was calculated and the tumor weight suppression rate in the control group was evaluated. As a result, the medicinal efficacy was confirmed at concentrations of 800ppm or higher. On the other hand, the UM-UC-3 model is a commonly used model, but it mimics CIS (carcinoma in situ) and can only partially mimic NMIBC. That is, other models are needed to evaluate efficacy for low- and high-grade NMIBC other than CIS. Therefore, we established high-grade and low-grade PDX and evaluated the effectiveness of HM-001 against low- and high-grade PDX through ex vivo testing. First, patient-derived tissue was transplanted into SCID mice, allowed to grow, and then removed. After extraction, they were cut into 2 mm3 pieces, exposed to HM-001 at 800, 1600, and 3200 ppm for 2 hours, and then transplanted into SCID mice. As a result of comparing the tumor size after transplantation with the control group, a dose-dependent tumor regression effect was confirmed in high-grade and low-grade PDX. NMIBC is divided into low-, medium-, and high-risk categories, with different treatment methods and drugs used for each. In particular, low-grade forms are restricted to low- and intermediate-risk groups. The results of this study show that HM-001 is effective not only for high-risk (including CIS) NMIBC but also for low- and intermediate-risk (low-grade) NMIBC.
Citation Format: Shinji Mima, Monta Sakaki, Noriaki Kiya, Atsunari Kawashima, Norio Nonomura, Chihaya Kakinuma. Development of HM-001 as a therapeutic drug for non-muscle invasive bladder cancer [abstract]. In: Proceedings of the AACR Special Conference on Bladder Cancer: Transforming the Field; 2024 May 17-20; Charlotte, NC. Philadelphia (PA): AACR; Clin Cancer Res 2024;30(10_Suppl):Abstract nr B024.
Abstract IA016: The evolving role of immune-based treatment strategies in metastatic urothelial cancer
Authors: Galsky Matthew D. 
Published: May 2024

Abstract
Immune checkpoint blockade has changed the treatment landscape for metastatic urothelial cancer. However, the role of PD-1/PD-L1 blockade in the treatment of metastatic diseaes continues to rapidly evolve since the initialy regulatory approval of these therapies in 2016. Defining biomarkers with sufficient predictive ability to establish clinical utility for selection of patients who can receive single agent PD-1/PD-L1 blockade has been challenging. However, combination regimens with either cisplatin-based chemotherapy or enfortumab vedotin has for the first time in decades improved survival compared with platinum-based chemotherapy alone. Refining the use of such combination regimens requires a better understanding of the potential immunomodulatory effects of cytotoxic therapies.
Citation Format: Matthew D. Galsky. The evolving role of immune-based treatment strategies in metastatic urothelial cancer [abstract]. In: Proceedings of the AACR Special Conference on Bladder Cancer: Transforming the Field; 2024 May 17-20; Charlotte, NC. Philadelphia (PA): AACR; Clin Cancer Res 2024;30(10_Suppl):Abstract nr IA016.
Relationship Between Genotype Status and Clinical Outcome in Hypertrophic Cardiomyopathy
Authors: Bonaventura Jiri , Rowin Ethan J. , Chan Raymond H. , Chin Michael T. , Puchnerova Veronika , Polakova Eva , Macek Milan , Votypka Pavel , Batorsky Rebecca , Perera Gayani , Koethe Benjamin , Veselka Josef , Maron Barry J. , Maron Martin S. 
Published: May 2024

Background
The genetic basis of hypertrophic cardiomyopathy (HCM) is complex, and the relationship between genotype status and clinical outcome is incompletely resolved.

Methods and Results

We assessed a large international HCM cohort to define in contemporary terms natural history and clinical consequences of genotype. Consecutive patients (n=1468) with established HCM diagnosis underwent genetic testing. Patients with pathogenic (or likely pathogenic) variants were considered genotype positive (G+; n=312; 21%); those without definite disease‐causing mutations (n=651; 44%) or variants of uncertain significance (n=505; 35%) were considered genotype negative (G−). Patients were followed up for a median of 7.8 years (interquartile range, 3.5–13.4 years); HCM end points were examined by cumulative event incidence. Over follow‐up, 135 (9%) patients died, 33 from a variety of HCM‐related causes. After adjusting for age, all‐cause and HCM‐related mortality did not differ between G− versus G+ patients (hazard ratio [HR], 0.78 [95% CI, 0.46–1.31];
P
=0.37; HR, 0.93 [95% CI, 0.38–2.30];
P
=0.87, respectively). Adverse event rates, including heart failure progression to class III/IV, heart transplant, or heart failure death, did not differ (G− versus G+) when adjusted for age (HR, 1.20 [95% CI, 0.63–2.26];
P
=0.58), nor was genotype independently associated with sudden death event risk (HR, 1.39 [95% CI, 0.88–2.21];
P
=0.16). In multivariable analysis, age was the only independent predictor of all‐cause and HCM‐related mortality, heart failure progression, and sudden death events.

Conclusions
In this large consecutive cohort of patients with HCM, genotype (G+ or G−) was not a predictor of clinical course, including all‐cause and HCM‐related mortality and risk for heart failure progression or sudden death. G+ status should not be used to dictate clinical management or predict outcome in HCM.
Probabilistic models for studying the potential spatial distribution of three intertidal decapods in the north of Chile (Taltal, 25°S, Antofagasta region)
Authors: De los Ríos-Escalante Patricio , Wilson Rodolfo , Ghory Farhana S. 
Published: May 2024

Abstract
The northern Chilean coast is characterized by its high productivity and diversity due to the presence of the cold, nutrient-rich water of the Humboldt Current. The coasts in the area are mainly bordered by rocky shores that provide many microhabitats for invertebrates. The aim of the present study was to analyse the spatial distribution of three sympatric intertidal decapods, Leptograpsus variegatus, Cyclograpsus cinereus and Petrolisthes granulosus, using probabilistic models. The studied locality was situated on the rocky shores of Taltal Bay, in the north of Chile. The counting of individuals could reveal the presence of the reported species, and if they did or did not coexist. The results revealed that L. variegatus and C. cinereus had a uniform pattern with Binomial distribition, whereas P. granulosus showed a random occurrence with Poisson distribution. These results would not coincide with classical observations of intertidal decapods on the rocky shores of continental Chile, as those denoted a gregarious pattern, but the distributions found would rather explain potential territorial behaviour.
Morphometric relationships and condition factor of the green tiger shrimp, Penaeus semisulcatus De Haan, 1844 (Decapoda, Penaeidae), from Palk Bay waters of Tamil Nadu
Authors: Rajkumar M. , Lakshmi Pillai S. , Muthaiyan Midun , Rajkumar R. , Thirumalaiselvan S. , Saravanan M. 
Published: May 2024

Abstract
Morphometric relationships and condition factors are essential for understanding any marine species’ development process, which aids in designing appropriate strategies for management and articulating their balance in the ecosystem — and this includes shrimps. Since only a few studies on these characteristics have been done in Penaeus semisulcatus over the last thirty years, constant updating of these criteria is required to successfully manage the shrimp fishery in Palk Bay. The CL-TW relationship demonstrates negative allometric growth in both males and females, whereas the TL-TW relationship exhibits positive allometric growth. In this present investigation, significant differences in slopes and elevations of the carapace length-total weight, total length-total weight, carapace length-total length, and total length-carapace length have been observed between sexes; considering the condition factors shown in the present investigation, the shrimps in Palk Bay were in good growing condition. This study has demonstrated that updated information on morphometric relationships would help fishery managers effectively manage the fisheries.